The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors
Official Title: A Phase I Dose Escalation Study of NMS-1286937 Administered to Adult Patients With Advanced/Metastatic Solid Tumors
Study ID: NCT01014429
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of NMS-1286937, a polo-like-kinase 1 inhibitor, in patients with advanced metastatic solid tumor.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Arizona TGen Clinical Research Services at Scottsdale Heathcare, Scottsdale, Arizona, United States
Name: Mariangela Mariani, Biol Sci D
Affiliation: Nerviano Medical Sciences
Role: STUDY_DIRECTOR
Name: Maria Adele Pacciarini, Biol Sci D
Affiliation: Nerviano Medical Sciences
Role: STUDY_DIRECTOR
Name: Glen J Weiss, MD
Affiliation: Arizona TGen Clinical Reserch Services at Scottsdale Healthcare
Role: PRINCIPAL_INVESTIGATOR